Brief: Clovis Oncology Highlights Phase 1 Data From Ongoing Clinical Studies Of Targeted Radiotherapy Candidate Fap-2286
14/06/2022 19:31
June 14 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY HIGHLIGHTS PHASE 1 DATA FROM ONGOING
CLINICAL
STUDIES OF TARGETED RADIOTHERAPY CANDIDATE FAP-2286 AT SNMMI
ANNUAL MEETING
* CLOVIS ONCOLOGY INC - NINE PATIENTS TREATED TO DATE WITH
(177)LU-FAP-2286 UP TO 5.5 GBQ/DOSE
* CLOVIS ONCOLOGY INC - CONFIRMED PARTIAL RESPONSE IN ONE
PATIENT
WHO COMPLETED SIX ADMINISTRATIONS OF (177)LU-FAP-2286 IN 3.7 GBQ
DOSE COHORT
* CLOVIS ONCOLOGY INC - RECRUITMENT OF 7.4 GBQ DOSE COHORT
IS
ONGOING
Source text for Eikon: ID:nBw1pJSBPa
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber